Folia Health announced a collaboration with argenx to launch a first-of-its-kind at-home observational real-world evidence initiative for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The study uses Folia's home-reported outcomes platform to capture symptom severity, treatment utilization, and daily disease management directly from patients and caregivers over a six-month period.

RTW Investments established a new $193 million position in Apellis Pharmaceuticals by acquiring 7.67 million shares in Q4 2025. Despite a 29% stock decline over the past year, the investment signals confidence in the company's commercial-stage biotech portfolio, which generated $689 million in product revenue driven by its flagship therapy. The position represents a calculated pivot toward more durable revenue streams within a portfolio focused on high-growth biotech names.

Unnatural Products, a biotech company developing orally-delivered macrocyclic peptides, closed a $45 million Series B funding round led by The Venture Collective. The company also announced a licensing agreement with Novartis worth up to $1.7 billion in total potential milestones for cardiovascular therapeutics. The platform combines attributes of biologics and small molecules to target previously undruggable disease targets.

Vyvgart (efgartigimod alfa-fcab), an FcRn inhibitor developed by Argenx, is experiencing significant market growth driven by rising autoimmune disease prevalence, regulatory approvals including a March 2024 Japan approval for ITP treatment, and a September 2025 manufacturing partnership with Fujifilm to expand production capacity. The market is expanding beyond generalized myasthenia gravis (gMG) into other indications with growing adoption of precision immunology and personalized treatments, though tariffs are pushing for localized manufacturing investments.

The American Kidney Fund (AKF) is launching its Kidney Month campaign on March 1, 2026, to raise awareness about kidney disease affecting 1 in 7 American adults. The campaign emphasizes early detection and prevention through the 'Kidneys Count' initiative and encourages people to pledge to discuss kidney health with their doctors. AKF will host Kidney Action Week (March 2-5) featuring expert sessions on kidney disease management and treatment options.

Argenx announced positive Phase 3 ADAPT OCULUS study results for VYVGART in treating ocular myasthenia gravis, meeting its primary endpoint with statistically significant improvement in patient-reported outcomes. The company reported strong Q4 earnings of $8.02 per share (beating consensus of $6.02) and sales of $1.32 billion (surpassing consensus of $1.29 billion). The results support a planned FDA supplemental application to expand VYVGART's label into oMG treatment.

argenx announced positive Phase 3 results for VYVGART in ocular myasthenia gravis (oMG), meeting its primary endpoint with statistical significance (p=0.012). The study showed significant improvement in ocular symptoms including diplopia and ptosis compared to placebo. The company plans to submit a Supplemental Biologics License Application (sBLA) to the FDA to expand VYVGART's label into oMG, representing the first targeted treatment specifically evaluated for this indication.

The generalized myasthenia gravis (gMG) market is expected to grow significantly through 2034, driven by novel immunotherapies including FABHALTA (iptacopan) from Novartis, Descartes-08 from Cartesian Therapeutics, and Claseprubart from Dianthus Therapeutics. The 7MM had approximately 205,000 prevalent gMG cases in 2024, with increasing incidence projected. These emerging therapies represent a shift toward mechanism-driven treatments targeting refractory disease and improving long-term disease control.

The biotech sector rebounded strongly in 2025 as M&A activity surged, becoming a stabilizing force for small and mid-cap companies. With 57% of biopharma acquisitions involving smaller firms and $30.9 billion in deals, investor sentiment shifted from GLP-1 drugs toward cancer and autoimmune disease treatments, particularly next-generation CAR-T therapies. Looking ahead to 2026, analysts expect continued M&A activity and strategic partnerships, though risks remain including FDA staff turnover and an 'IPO air pocket' from the 2023-2024 downturn.

Argenx discontinued its Phase 3 UplighTED studies evaluating efgartigimod for thyroid eye disease after an Independent Data Monitoring Committee recommended stopping the trials for futility, despite a favorable safety profile.

Denali Therapeutics appointed Tim Van Hauwermeiren to its Board of Directors and announced the departure of Chief Medical Officer Carole Ho to Eli Lilly, with Peter Chin assuming the Acting Chief Medical Officer role.

Pharmaceutical company argenx presented clinical trial data demonstrating VYVGART's effectiveness in treating generalized myasthenia gravis across different patient subtypes, including seronegative patients, with promising results in symptom reduction and steroid use management.